Abeona Therapeutics

Abeona Therapeutics

Develops gene therapy-based potential cures for Sanfilippo syndrome types A and B.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
N/A

€0.0

round
N/A

€0.0

round
investor

€0.0

round
N/A

€0.0

round
investor

€0.0

round
investor investor investor investor investor

€0.0

round
investor

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
investor

€0.0

round
*

$75.0m

Post IPO Equity
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
USD2020202120222023202420252026
Revenues0000000000000000000000000000
% growth-(70 %)(53 %)148 %--121 %
EBITDA0000000000000000000000000000
% EBITDA margin(426 %)(1802 %)(3160 %)(1141 %)---
Profit0000000000000000000000000000
% profit margin(842 %)(2831 %)(2807 %)(1548 %)---
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000
R&D % of revenue301 %1144 %2048 %888 %---

Source: Company filings or news article, Equity research estimates

More about Abeona Therapeutics
Made with AI
Edit

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cell and gene therapies to treat serious diseases, particularly genetic disorders. The company operates in the biopharmaceutical industry, which involves the development of medical treatments using biological sources. Abeona's primary clients are patients suffering from severe genetic conditions, especially those with high unmet medical needs, such as genetic eye disorders.

Abeona's business model revolves around researching, developing, and eventually commercializing gene therapies. Gene therapy involves using DNA to treat diseases by delivering the correct copy of a gene into a patient's cells. This approach is particularly promising for genetic disorders caused by a single genetic defect. One of Abeona's key projects is ABO 50X, which is being explored for its potential to treat genetic eye disorders.

The company generates revenue through various stages of its development process. Initially, funding comes from investors who believe in the potential of Abeona's therapies. As the therapies progress through clinical trials and receive regulatory approval, the company can then commercialize these treatments, generating income from sales and possibly licensing agreements.

Abeona Therapeutics is committed to transforming the lives of patients by harnessing the promise of genetic medicine. Their vision is to make cures the new standard of care, moving beyond treatments that only manage symptoms.

Keywords: gene therapy, genetic disorders, biopharmaceutical, cell therapy, clinical-stage, ABO 50X, ophthalmic diseases, DNA therapy, serious diseases, patient-focused.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo